Skip to content
Company Analysis

Dr. Reddy's Laboratories Ltd RDY

A comprehensive view of key metrics, scores, and financial health for Dr. Reddy's Laboratories Ltd

Overview of Dr. Reddy's Laboratories Limited

RDY NYQ
Healthcare Drug Manufacturers - Specialty & Generic Large Cap
Dr. Reddy's Laboratories Limited (RDY), is a Large Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $14.13, about 6225.3% undervalued vs fair value, +6.9% 1Y return, placing in the top 25% of its sector.
$14.13
-1.53%
As of March 13, 2026
Previous close • Vol 90d: 17.3%
52-Week Range
Market Cap
$12.02B
Enterprise Value
$-2.84B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Dr. Reddy's Laboratories Ltd.

Top Beats

Quick Facts

Website https://www.drreddys.com
HQ Hyderabad
Employees 27,811
Fiscal year Mar 31

Next Events

Earnings May 7 Estimated

Fair Value Snapshot

Bear Base Bull
$819
$894
$974
Current: $14.13 +6225% vs base

Engine Room Money Flow™

Large Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$325.5B
16.6%%
Gross Profit
$190.4B
16.4%%
R&D Expense
$27.4B
19.7%%
Operating Income (EBIT)
$79.6B
8.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
58.3%
Poor

Weak cash conversion - investigate working capital

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$8.1B
66.9% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
0/3
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Dr. Reddy's Laboratories Ltd's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
72
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
77
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing RDY's balance between Growth (31.3%), Profitability (39.2%), and Safety (29.5%). Growth 31% Safety 29% Profitability 39%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

64th percentile vs peers
65
Key Signals
Rev Growth YoY 16.6% 66p Revenue CAGR 3Y 14.9% 67p EPS CAGR 3Y 33.7% 81p TSR 97.2% 82p EPS Growth YoY 1.5% 38p
Strengths
  • Eps Cagr 3Y in top 20% of peers (33.7%, 81th percentile)
  • Interest Coverage Ratio in top 20% of peers (28.14, 98th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (100%)
Risks

No significant risks identified for this axis.

Profitability

81th percentile vs peers
81
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

61th percentile vs peers
61
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Dr. Reddy's Laboratories Ltd.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$893.76
- - -
+6225.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info